In reply [5]

JAMA

Volumn 296, Issue 18, 2006, Pages 2203-2204

  Bongartz, Tim ^a   Matteson, Eric L ^a   Montori, Victor M ^a   Sutton, Alex J ^b   Sweeting, Michael ^c   Buchan, Iain ^d  

^a Mayo Clinic   (United States)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR ANTIBODY;

CANCER; CANCER RISK; CLINICAL TRIAL; DOSE RESPONSE; HUMAN; INFECTION; LETTER; META ANALYSIS; PRIORITY JOURNAL; RHEUMATIC DISEASE; SYSTEMATIC REVIEW;

EID: 33750689118     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: None     Document Type: Letter

References (8)

1. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37.
2. Westhovens R, Yocum D, Han J, et al; START Study Group. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum. 2006;54:1075-1086.
3. Lievre M, Cucherat M, Leizorovicz A. Pooling, meta-analysis, and the evaluation of drug safety. Curr Control Trials Cardiovasc Med. 2002;3:6.
4. Stern R, Wolfe F. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol. 2004;31:1538-1545.
5. Infliximab package insert. http://www.remicade.com/global/hcp/hcp_PI.jsp. Accessed September 13, 2006.
6. Hatala R, Keitz S, Wyer P, Guyatt G. Tips for learners of evidence-based medicine, 4: assessing heterogeneity of primary studies in systematic reviews and whether to combine their results. CMAJ. 2005;172:661-665.
7. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748.
8. European Medicines Agency Scientific discussion. June 23, 2005. http://www.emea.eu.int/humandocs/PDFs/EPAR/humira/EMEA-H-481-II-21-%20AR.pdf. Accessed September 13, 2006.